BioLineRx Ltd. (NASDAQ:BLRX) posted its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.05 on Thursday. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63. The company has a 50 day moving average price of $1.06 and a 200-day moving average price of $0.94.

Earnings History for BioLineRx (NASDAQ:BLRX)

A number of large investors have recently bought and sold shares of BLRX. Senvest Management LLC increased its stake in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares during the period. KCG Holdings Inc. increased its stake in BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock worth $174,000 after buying an additional 121,650 shares during the period. Finally, Morgan Stanley increased its stake in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares during the period. 14.35% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have issued reports on the company. Maxim Group set a $1.00 target price on BioLineRx and gave the stock a “hold” rating in a research report on Tuesday. S&P Equity Research dropped their target price on BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. Roth Capital restated a “buy” rating and set a $7.00 target price on shares of BioLineRx in a research report on Sunday, August 14th. Finally, Zacks Investment Research downgraded BioLineRx from a “buy” rating to a “hold” rating in a research report on Tuesday, October 11th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $2.68.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/biolinerx-ltd-blrx-posts-quarterly-earnings-results.html.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.